Please login to the form below
Fasenra
This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.
AZ says dropping MedImmune will help ‘streamline’ its R&D
The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted
Latest news
-
Cancer drugs and China sustain AZ’s return to growth
Among these, severe asthma therapy Fasenra (benralizumab) shrugged off a tough competitive environment to post $297m in sales in its first full-year on the market despite going toe-to-toe
-
AZ says target of $45bn sales by 2023 still achievable
The underlying picture is strong, however, with new medicines like Tagrisso, Imfinzi, Lynparza in cancer, Farxiga in diabetes and Fasenra in severe asthma growing 19% in the first nine months of ... In respiratory, interleukin-5 inhibitor Fasenra
-
Dupixent helps put Sanofi back on growth track
Fasenra (benralizumab) all jostling for market share.
-
FDA rejects GSK’s Nucala for COPD
Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab). ... In May, AZ’s Fasenra failed a phase III trial in this indication as it was unable to show a benefit compared to placebo reducing exacerbations.
-
AZ, Amgen’s first-in-class asthma drug gets breakthrough status
Drugs like Fasenra and GlaxoSmithKline’s rival IL-5 inhibitor Nucala (mepolizumab) have emerged as an important treatment option for people with severe asthma characterised by high levels of eosinophils. ... Nucala made £245m ($317m) in the first six
More from news
Approximately 6 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
-
Director – Healthcare PR
-
Salary TBC
-
Senior Medical Writer
-
Competitive salary and benefits
-
Senior Medical Writer
-
Salary TBC
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Account Director, Medical Education
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Editor – Medical Education Agency – Bucks
-
Salary TBC
Subscribe to our email news alerts
- With Spiriva under pressure, Boehringer moves to bolster pipeline
- Genfit claims FDA breakthrough status for liver disease drug
- Mereo’s shareholders back OncoMed takeover
- Lucid Group announces the appointment of new CFO
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- Q&A: Niels Lund
PMHub
Complete HealthVizion
Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...
Latest intelligence
- From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
- How pharma is progressing their commitment in patient engagement...
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
Quick links
Infographics
